The ETERNAL Horizon Europe Research and Innovation Action has just made seven industrial case study summaries publically available. The easily-read two-page documents provide a concise summary of the key features, progress to date, and further steps involved as several of the project's applied research efforts start to yield fruit in an at or near industrial ready state.

This video describes how concerted efforts in ETERNAL's case studies distributed across a range of industrial use cases and the extended value chain for pharmaceuticals are making a real and positive impact upon the future sustainability and competitiveness of the sector.

This newsletter, the sixth since the ETERNAL project started, provides ample opportunities to dig deeper into both the project’s research illuminating the environmental risks surrounding pharmaceutical manufacture and positive responses from the industry to minimize the risks through technological innovation and standardization for less impactful, more efficient, sustainable and safe by design processes.

Two scientific posters on the industrial case studies which they are leading in ETERNAL were presented by Angelini Pharma in the context of a dissemination event for the LIFE-GREENAPI project hosted at its Fine Chemicals plant in Aprilia. Find out more about optimized use of solvents in API manufacture and the use of twin screw extrusion processing in pharmaceutical development.

The ETERNAL project consortium's 5th General Assembly meeting in Barcelona on 24th and 25th October 2024 heard reports of continuing strong progress as the project's six industrial case study teams start to transition the focus of their work towards scale up for impact.

The ETERNAL project recently contributed to the success of a well-received Speciality Chemicals Symposium run by the Royal Society of Chemistry in conjunction with the Chemspec Europe 2024 exhibition in Düsseldorf, Germany.